%0 Journal Article
%T Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer
%A Heather Cheng
%A Jacquelyn Powers
%A Kerry Schaffer
%A Oliver Sartor
%J About the Ed Book | ASCO Educational Book
%D 2018
%R https://doi.org/10.1200/EDBK_205441
%X Over the past several years, it has become abundantly clear that molecular events not only can be defined in prostate cancer but also can affect the treatment of patients and can have important implications for family members. A substantial proportion of aggressive prostate cancers (approximately 25%) have characteristic DNA repair alterations that suggest precision therapy opportunities; approximately 10% have alterations found in the germline and potentially represent inherited cancer predisposition. These findings have led to rapid and far-reaching changes to the field that include exciting new precision treatment opportunities and increased responsibility and challenges surrounding tumor genomic profiling and genetic counseling around inherited cancer risk. GENOMICS VERSUS GENETICS AND IMPLICATIONS FOR PROSTATE CANCER CARE Section: ChooseTop of pageAbstractGENOMICS VERSUS GENETICS ... <<HOMOLOGOUS RECOMBINATION ...GERMLINE DNA REPAIR DEFEC...PRECISION MEDICINE FOR PR...AVAILABILITY OF GERMLINE ...WHO TO TEST FOR GERMLINE ...ASSAYS FOR SOMATIC GENETI...CLINICAL ACTIONABILITY OF...SOMATIC GENETICS: WHO TO ...PRACTICAL GUIDANCE ON GEN...KEY DISCUSSION POINTS FOR...References In 2015, The Cancer Genome Atlas Research Network reported findings from 333 primary prostate cancers and the identification of 19% of primary tumors with mutations in DNA repair genes, including 3% in the homologous recombination repair gene, BRCA2.1 That same year, the International Stand Up to Cancer/Prostate Cancer Foundation/American Association for Cancer Research Prostate Cancer Dream Team applied exome sequencing to 150 metastatic biopsies and found that 23% of metastatic prostate cancers carry alterations in genes critical for DNA repair, again involving homologous recombination repair (BRCA2, ATM, and BRCA1) as well as mismatch repair (MLH1 and MSH2).2 Unexpectedly, 8% of the DNA repair mutations were found in the germline DNA, the first indication that there may be a higher than previously recognized prevalence of cancer predisposition among men with metastatic prostate cancer. These discoveries represented major strides in the field and a new era marked by greater interplay between somatic genomics and germline genetics. HOMOLOGOUS RECOMBINATION DNA REPAIR DEFECTS AND NEW TREATMENT STRATEGIES Section: ChooseTop of pageAbstractGENOMICS VERSUS GENETICS ...HOMOLOGOUS RECOMBINATION ... <<GERMLINE DNA REPAIR DEFEC...PRECISION MEDICINE FOR PR...AVAILABILITY OF GERMLINE ...WHO TO TEST FOR GERMLINE ...ASSAYS FOR SOMATIC GENETI...CLINICAL ACTIONABILITY OF...SOMATIC GENETICS: WHO
%U http://ascopubs.org/doi/full/10.1200/EDBK_205441